MRNA

SEC source: 0001127602-20-019271 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 563,762

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.81 to $58.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-019271 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 569,599

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.78 to $57.78. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-018880 · form4.xml · derivative · entry 11

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 443,550

Underlying: Common Stock · 39,752 shares

Expires 2026-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F9 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001127602-20-018880 · form4.xml · derivative · entry 10

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,243

Underlying: Common Stock · 47,737 shares

Expires 2028-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F8 · derivative.exercise_date: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-20-018880 · form4.xml · derivative · entry 9

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,412

Underlying: Common Stock · 11,467 shares

Expires 2027-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F7 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 8

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.69 to $59.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 7

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,525

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.67 to $59.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 6

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,906

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.65 to $58.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,985

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.61 to $57.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,782

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.60 to $56.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,956

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,204

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018883 · form4.xml · derivative · entry 7

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 96,660 shares

Expires 2026-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001127602-20-018883 · form4.xml · derivative · entry 6

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 578,372

Underlying: Common Stock · 66,031 shares

Expires 2026-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001127602-20-018883 · form4.xml · derivative · entry 5

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 587,735

Underlying: Common Stock · 78,309 shares

Expires 2028-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2 · derivative.exercise_date: 458,715 of the options will vest over 4 years (25% on February 27, 2019, then quarterly for the next 3 years), 229,358 of the options will vest over 5 years (25% on February 27, 2020, then quarterly for the next 3 years), 229,358 of the options will vest over 6 years (25% on February 27, 2021, then quarterly for the next 3 years).

SEC source: 0001127602-20-018883 · form4.xml · nonDerivative · entry 4

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,202,510

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018883 · form4.xml · nonDerivative · entry 3

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,443,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018883 · form4.xml · nonDerivative · entry 2

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,346,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018883 · form4.xml · nonDerivative · entry 1

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,280,819

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018531 · form4.xml · nonDerivative · entry 6

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,193,839

F7 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/18/2018, and amended on 9/16/2019.

F9 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-018531 · form4.xml · nonDerivative · entry 5

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,875,124

F7 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/18/2018, and amended on 9/16/2019.

F8 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-018531 · form4.xml · nonDerivative · entry 4

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,729,980

F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/18/2018.

SEC source: 0001127602-20-019269 · form4a.xml · nonDerivative · entry 4

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,193,839

F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/18/2018, as amended on 9/16/2019.

F7 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-018531 · form4.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 574,408

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.12 to $61.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-018531 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 574,871

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.75 to $58.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-018531 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 582,691

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.72 to $57.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-019269 · form4a.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 574,408

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.12 to $61.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-019269 · form4a.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 574,871

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.75 to $58.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-019269 · form4a.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 582,691

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.72 to $57.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-018084 · form4.xml · derivative · entry 5

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 666,044

Underlying: Common Stock · 222,365 shares

Expires 2028-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · derivative.exercise_date: 458,715 of the options will vest over 4 years (25% on February 27, 2019, then quarterly for the next 3 years), 229,358 of the options will vest over 5 years (25% on February 27, 2020, then quarterly for the next 3 years), 229,358 of the options will vest over 6 years (25% on February 27, 2021, then quarterly for the next 3 years).

SEC source: 0001127602-20-018084 · form4.xml · derivative · entry 4

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,909

Underlying: Common Stock · 18,635 shares

Expires 2027-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018, with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-20-018084 · form4.xml · nonDerivative · entry 3

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,202,510

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018084 · form4.xml · nonDerivative · entry 2

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,443,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018084 · form4.xml · nonDerivative · entry 1

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,424,875

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018077 · form4.xml · nonDerivative · entry 8

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,996,540

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-20-018077 · form4.xml · nonDerivative · entry 7

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,996,740

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.65 to $65.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018077 · form4.xml · nonDerivative · entry 6

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,997,540

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.46 to $64.36. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018077 · form4.xml · nonDerivative · entry 5

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,998,540

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.09 to $63.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018077 · form4.xml · nonDerivative · entry 4

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,450

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.08 to $62.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018077 · form4.xml · nonDerivative · entry 3

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,004,213

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.07 to $61.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018077 · form4.xml · nonDerivative · entry 2

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,005,395

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-20-018077 · form4.xml · nonDerivative · entry 1

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,005,495

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.38 to $58.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-018080 · form4.xml · derivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,980

Underlying: Common Stock · 42,570 shares

Expires 2028-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-20-018080 · form4.xml · derivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,760

Underlying: Common Stock · 82,474 shares

Expires 2027-10-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

SEC source: 0001127602-20-018080 · form4.xml · nonDerivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018080 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,044

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018080 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,570

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-018898 · form4a.xml · nonDerivative · entry 1

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,996,540

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018.

SEC source: 0000899243-20-014188 · doc4.xml · nonDerivative · entry 16

Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner

Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner

Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 6,420,766

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.10 to $70.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.